ReviewKidney international2015
A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010.
Review in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 413 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
413 citing papers in PubMed, 9 syntheses or guidelines pooled it, 860 citations in OpenAlex.
- Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.Blood advances · 2026Pooled it
- Conservative kidney management versus dialysis for stage 5 chronic kidney disease in older people.The Cochrane database of systematic reviews · 2025Pooled it
- Artificial intelligence in predicting chronic kidney disease prognosis. A systematic review and meta-analysis.Renal failure · 2024Pooled it
- Food insecurity and kidney disease: a systematic review.International urology and nephrology · 2024Pooled it
- Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.BMC nephrology · 2024Pooled it
- Pooled it
- Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Pooled it
- Kidney transplantation: a possible solution to obstructive sleep apnea in patients with end-stage kidney disease.Sleep & breathing = Schlaf & Atmung · 2023Pooled it
- Prevalence of chronic kidney disease stages 3-5 in low- and middle-income countries in Asia: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Effect of the Chronic Kidney Disease-Peritoneal Dialysis (CKD-PD) App on Improvement of Overhydration Treatment in Patients on Peritoneal Dialysis: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- PREDICT Tool for Pregnancy-Associated CKD Progression.Kidney international reports · 2026Article
- Predictors of Primary Arteriovenous Fistula Failure in Patients With End-Stage Renal Disease: A Single-Centre Retrospective Cohort.Health science reports · 2026Article
- Interferon-λ drives renal fibrosis by coordinating epithelial-fibroblast crosstalk.The Journal of experimental medicine · 2026Article
- Article
- Ageing impacts extracellular matrix turnover and remodelling in the kidney.Matrix biology plus · 2026Article
- Citrate-Dependent Activation of Acetyl CoA Carboxylase Promotes Renal Lipid Accumulation in a Rat Model of Chronic Kidney Disease.Acta physiologica (Oxford, England) · 2026Article
- Awareness and factors associated with routine medical checkups for non-communicable diseases among adults in Gondar City, Ethiopia.Scientific reports · 2026Article
- Body composition paradox: high muscle mass and adiposity jointly predict incident chronic kidney disease in a Korean cohort.Clinics (Sao Paulo, Brazil) · 2026Article
- Nephrology Survey on Reproductive Health and Kidney Disease.Kidney international reports · 2026Article
- The Influence of Aerobic and Strength Training on Oxidative Stress and Antioxidant Status in Hemodialysis Patients: A Randomized Controlled Trial.Health science reports · 2026Article
353 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Chronic kidney disease (CKD) is a major risk factor for end-stage renal disease, cardiovascular disease, and premature death. Here we estimated the global prevalence and absolute burden of CKD in 2010 by pooling data from population-based studies. We searched MEDLINE (January 1990 to December 2014), International Society of Nephrology Global Outreach Program-funded projects, and bibliographies of retrieved articles and selected 33 studies reporting gender- and age-specific prevalence of CKD in representative population samples. The age-standardized global prevalence of CKD stages 1-5 in adults aged 20 and older was 10.4% in men (95% confidence interval 9.3-11.9%) and 11.8% in women (11.2-12.6%). This consisted of 8.6% in men (7.3-9.8%) and 9.6% in women (7.7-11.1%) in high-income countries, and 10.6% in men (9.4-13.1%) and 12.5% in women (11.8-14.0%) in low- and middle-income countries. The total number of adults with CKD was 225.7 million (205.7-257.4 million) men and 271.8 million (258.0-293.7 million) women. This consisted of 48.3 million (42.3-53.3 million) men and 61.7 million (50.4-69.9 million) women in high-income countries, and 177.4 million (159.2-215.9 million) men and 210.1 million (200.8-231.7 million) women in low- and middle-income countries. Thus, CKD is an important global-health challenge, especially in low- and middle-income countries. National and international efforts for prevention, detection, and treatment of CKD are needed to reduce its morbidity and mortality worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.